Akums Drugs and Pharmaceuticals, a Contract Development and Manufacturing Organisation (CDMO), has reported strong financial performance for the quarter ended June 30, 2026, marking a positive start to FY27. The company recorded growth across revenue, operating profitability and profit after tax, supported by sustained momentum in its CDMO business, improved operational efficiency and healthy customer demand.

The company reported operating revenue of INR 1,167 crore for Q1 FY27, registering a 13.9 percent year-on-year increase from INR 1,024 crore in Q1 FY26. EBITDA rose 35.4 percent YoY to INR 175 crore, compared with INR 129 crore in the corresponding quarter last year. The EBITDA margin consequently improved to 15.0 percent from 12.6 percent.

Akums also reported a significant improvement in profitability. Profit After Tax (PAT) increased to INR 101 crore, compared with INR 65 crore in Q1 FY26, representing a growth of approximately 55.4 percent year-on-year. PAT margin improved to 8.4 percent from 6.2 percent during the same period.

The company’s CDMO business remained the primary growth engine during the quarter. CDMO revenue increased to INR 964 crore from INR 813 crore in Q1 FY26, reflecting continued demand for its manufacturing and development capabilities. CDMO EBITDA grew 36.8 percent YoY to INR 163 crore, compared with INR 119 crore in the year-ago quarter.

According to the company, the growth in its CDMO segment was supported by continued volume expansion and an improvement in API prices. The performance highlights the sustained demand for outsourced pharmaceutical development and manufacturing services and the company’s position as a manufacturing partner for pharmaceutical customers.

Sanjeev Jain, Managing Director, Akums Drugs and Pharmaceuticals, said that the company’s strong opening quarter reflects a healthy demand environment and continued customer confidence in Akums as a preferred manufacturing partner.

Sandeep Jain, Managing Director, said the company remains focused on strengthening its CDMO leadership, expanding high-value capabilities and improving operational excellence. He added that a strong business pipeline and disciplined capital allocation provide a foundation for sustainable growth.

The Q1 FY27 performance comes as pharmaceutical companies increasingly leverage CDMO partners for manufacturing capacity, specialised capabilities and supply-chain requirements. Akums said it will continue to focus on expanding its capabilities and improving operational efficiency to support long-term growth.